ATE453629T1 - Chinazolin-verbindungen als ionenkanal modulatoren - Google Patents

Chinazolin-verbindungen als ionenkanal modulatoren

Info

Publication number
ATE453629T1
ATE453629T1 AT04716887T AT04716887T ATE453629T1 AT E453629 T1 ATE453629 T1 AT E453629T1 AT 04716887 T AT04716887 T AT 04716887T AT 04716887 T AT04716887 T AT 04716887T AT E453629 T1 ATE453629 T1 AT E453629T1
Authority
AT
Austria
Prior art keywords
ion channel
channel modulators
quinazoline compounds
quinazoline
compounds
Prior art date
Application number
AT04716887T
Other languages
English (en)
Inventor
Jesus Gonzales
Dean Wilson
Andreas Termin
Peter Grootenhuis
Yulian Zhang
Benjamin Petzoldt
Lev Fanning
Timothy Neubert
Roger Tung
Esther Martinborough
Nicole Zimmermann
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of ATE453629T1 publication Critical patent/ATE453629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04716887T 2003-03-03 2004-03-03 Chinazolin-verbindungen als ionenkanal modulatoren ATE453629T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45145803P 2003-03-03 2003-03-03
US46379703P 2003-04-18 2003-04-18
PCT/US2004/006451 WO2004078733A1 (en) 2003-03-03 2004-03-03 Quinazolines useful as modulators of ion channels

Publications (1)

Publication Number Publication Date
ATE453629T1 true ATE453629T1 (de) 2010-01-15

Family

ID=32965550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04716887T ATE453629T1 (de) 2003-03-03 2004-03-03 Chinazolin-verbindungen als ionenkanal modulatoren

Country Status (20)

Country Link
US (2) US7678802B2 (de)
EP (1) EP1608632B1 (de)
JP (1) JP5247027B2 (de)
KR (1) KR20050108379A (de)
AR (1) AR044502A1 (de)
AT (1) ATE453629T1 (de)
AU (1) AU2004217891B2 (de)
BR (1) BRPI0408026A (de)
CA (1) CA2517844A1 (de)
CL (1) CL2004000409A1 (de)
DE (1) DE602004024873D1 (de)
ES (1) ES2338553T3 (de)
IL (1) IL170636A (de)
NO (1) NO20054546L (de)
NZ (1) NZ542664A (de)
PE (1) PE20041059A1 (de)
RU (1) RU2378260C2 (de)
TW (1) TW200426147A (de)
UY (1) UY28215A1 (de)
WO (1) WO2004078733A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713983B2 (en) * 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2004092196A2 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
JP2007524615A (ja) * 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
AR045037A1 (es) * 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
EP1687002A4 (de) * 2003-11-10 2008-07-23 Synta Pharmaceuticals Corp Kondensierte heterozyklische verbindungen
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2006028904A1 (en) * 2004-09-02 2006-03-16 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2006066044A2 (en) * 2004-12-17 2006-06-22 Vertex Pharmaceuticals Incorporated Processes for producing 4-aminoquinazolines
WO2006097441A1 (en) * 2005-03-14 2006-09-21 Neurosearch A/S Potassium channel modulating agents and their medical use
WO2006127329A1 (en) * 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Quinoline derivatives useful as modulators of ion channels
FR2891829A1 (fr) * 2005-10-12 2007-04-13 Sanofi Aventis Sa Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
ATE540033T1 (de) 2005-11-14 2012-01-15 Vertex Pharma Als modulatoren von spannungsgesteuerten ionenkanälen geeignete chinazoline
KR20080070749A (ko) 2005-11-23 2008-07-30 페인셉터 파마 코포레이션 개폐 이온 통로를 조절하기 위한 조성물 및 방법
AU2006329202A1 (en) * 2005-12-21 2007-06-28 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20080004282A1 (en) * 2006-04-10 2008-01-03 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
AU2007245496A1 (en) 2006-04-26 2007-11-08 Cancer Research Technology Limited Amino-ethyl-amino-aryl (AEAA) compounds and their use
KR20090021218A (ko) 2006-06-12 2009-02-27 버텍스 파마슈티칼스 인코포레이티드 이온 채널의 조절제로서 유용한 티에노피리미딘
EP2061764B1 (de) * 2006-08-22 2014-07-02 Technion Research & Development Foundation LTD. An den peripheral-type-benzodiazepin-rezeptor (pbr) bindende heterocyclische derivate
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CA2663436A1 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
AU2007328336B2 (en) * 2006-12-01 2014-04-17 President And Fellows Of Harvard College Compounds and methods for enzyme-mediated tumor imaging and therapy
JP5642973B2 (ja) * 2007-03-22 2014-12-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｊａｋ阻害薬として有用なｎ−複素環式化合物
WO2008142384A1 (en) * 2007-05-17 2008-11-27 Helperby Therapeutics Limited Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2009000085A1 (en) * 2007-06-27 2008-12-31 Painceptor Pharma Corporation Quinoline and quinazoline derivatives useful as modulators of gated ion channels
WO2009053694A1 (en) * 2007-10-24 2009-04-30 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
BRPI0922010A2 (pt) * 2008-11-14 2015-12-15 Hoffmann La Roche dervivados de quinazolina como antagonistas receptores de nk3
WO2010135568A1 (en) * 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
EP2432779A1 (de) * 2009-05-22 2012-03-28 Exelixis, Inc. Auf benzoxazepinen basierende p13k/mt0r-hemmer gegen proliferative erkrankungen
WO2010151597A1 (en) * 2009-06-26 2010-12-29 Schering Corporation Methods for using pyrrolo-benzo-1,4-diazines as sodium channel blockers
US20110053916A1 (en) * 2009-08-14 2011-03-03 Vertex Pharmaceuticals Incorporated Pyrimidine compounds as tuberculosis inhibitors
ES2900504T3 (es) * 2009-09-03 2022-03-17 Bristol Myers Squibb Co Quinazolinas como inhibidores de los canales iónicos de potasio
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
AU2011311238A1 (en) 2010-10-05 2013-04-04 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
CN103360382B (zh) * 2012-03-26 2016-04-27 中国科学院福建物质结构研究所 喹唑啉衍生物及其用途
US9260436B2 (en) 2012-06-22 2016-02-16 Sumitomo Chemical Company, Limited Fused heterocyclic compound
US20150259649A1 (en) 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2014143609A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
AU2014298051B2 (en) 2013-07-31 2018-11-15 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
CA2928665A1 (en) * 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN103755649A (zh) * 2013-12-31 2014-04-30 李增 一种喹唑啉衍生物及其作为血管生成抑制剂的应用
EP3110794A1 (de) * 2014-02-27 2017-01-04 Merck Patent GmbH Heterocyclische verbindungen als nav-kanalinhibitoren und verwendungen davon
EP3134389B1 (de) 2014-04-23 2021-04-14 Technion Research & Development Foundation Limited Quinazolingerüstbasierte verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung davon
CN107427506A (zh) * 2014-10-14 2017-12-01 拉霍拉敏感及免疫学研究所 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
WO2016090299A1 (en) * 2014-12-05 2016-06-09 Subramaniam Ananthan Novel quinazolines as biogenic amine transport modulators
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
CA2966450A1 (en) 2014-12-17 2016-06-23 Olesya KHARENKO Inhibitors of bromodomains
CA2974078A1 (en) * 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
US11221329B2 (en) * 2015-10-30 2022-01-11 Lieber Institute, Inc. Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR102327053B1 (ko) * 2017-03-16 2021-11-17 기초과학연구원 퀴나졸린, 퀴놀린 유도체 및 egfr 키나제 억제제로서의 용도
US11066420B2 (en) 2017-05-01 2021-07-20 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof
US12291533B2 (en) 2017-08-02 2025-05-06 Northwestern University Substituted fused pyrimidine compounds and uses thereof
JP7315564B2 (ja) * 2018-02-02 2023-07-26 アジレント・テクノロジーズ・インク グリカン分析のためのブロックされた２－ａａを使用するための方法およびキット
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
JP7566753B2 (ja) 2019-01-03 2024-10-15 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 転写因子ｅｂポリペプチドレベルを増加させるための方法および材料
CN114401935B (zh) * 2019-12-14 2024-04-05 上海市东方医院（同济大学附属东方医院） 离子通道拮抗剂/阻断剂及其用途
EP4135698A4 (de) 2020-04-17 2024-08-14 The Trustees of Indiana University Kleinmolekülige antivirale wirkstoffbehandlung für humane papillomavirusinfektionen
EP4727553A2 (de) 2023-06-13 2026-04-22 The Trustees of Indiana University Kleinmolekülige antivirale wirkstoffbehandlung für humane papillomavirusinfektionen

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE119051C (de)
NL292083A (de) * 1962-09-18
US3340260A (en) * 1962-12-03 1967-09-05 Ciba Geigy Corp 4-amino-pyrimidines
GB1199768A (en) * 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
US3637693A (en) * 1968-07-12 1972-01-25 Du Pont Hydroxyarylquinazolines and their use as uv-absorbers
US3705898A (en) * 1970-01-26 1972-12-12 Morton Norwich Products Inc Certain 4 - amino - 2-(5-nitro-2-thienyl) quinazolines and the intermediate 4 - chloro-(5 - nitro-2-thienyl)quinazolines therefor
DE2121031A1 (en) * 1971-04-29 1972-11-02 Dr. Karl Thomae Gmbh, 7950 Biberach Base-substd quinazolines - thrombocyte aggregation inhibitors
US3819628A (en) * 1972-07-31 1974-06-25 Sandoz Ag 2-phenyl-4-substituted amino-quinazolines and nitrates thereof
CH612432A5 (de) * 1975-05-12 1979-07-31 Sandoz Ag
US4377582A (en) * 1979-12-19 1983-03-22 A. H. Robins Company, Inc. 2-Phenyl-4-[cis-2,5-dimethyl-4-(2-pyridinyl)-1-piperazinyl]quinazoline
US4306065A (en) * 1979-12-19 1981-12-15 A. H. Robins Company, Incorporated 2-Aryl-4-substituted quinazolines
JPS56120768A (en) * 1980-01-31 1981-09-22 Ciba Geigy Ag Color developing quinazoline compound
JPS58172379A (ja) 1982-04-02 1983-10-11 Showa Denko Kk 新規なキナゾリン誘導体
US5624918A (en) 1993-06-17 1997-04-29 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivatives
JP3722858B2 (ja) * 1993-11-25 2005-11-30 ビーエーエスエフ アクチェンゲゼルシャフト ポリアクリレート溶融体から残留揮発分を除去する方法
JPH083144A (ja) 1994-06-21 1996-01-09 Chugai Pharmaceut Co Ltd キナゾリン及びキノリン誘導体
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
FR2751656B1 (fr) * 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CA2239227C (en) 1996-10-01 2007-10-30 Kyowa Hakko Kirin Co., Ltd. Nitrogen-containing heterocyclic compounds
BR9714394A (pt) 1996-12-13 2000-05-16 Lilly Co Eli Inibidores da atividade enzimática de psa
JP3989102B2 (ja) * 1997-10-02 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリジン誘導体
DE19747063A1 (de) * 1997-10-24 1999-04-29 Basf Ag 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP3018185B1 (ja) 1999-02-12 2000-03-13 工業技術院長 キナゾリン誘導体又はその塩の製造方法
JP2001068452A (ja) * 1999-08-26 2001-03-16 Matsushita Electric Ind Co Ltd 回路パターン形成済シリコン基板のエッチング装置およびエッチング方法
JP2001089452A (ja) 1999-09-22 2001-04-03 Sankyo Co Ltd ピリミジン誘導体
ES2156574B1 (es) 1999-11-18 2002-02-01 Vita Invest Sa Nuevos derivados de tiazolidindiona como agentes antidiabeticos
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
DK1308439T3 (da) 2000-08-10 2009-01-12 Mitsubishi Tanabe Pharma Corp Prolinderivater og anvendelse af disse som lægemidler
CA2422488A1 (en) * 2000-09-20 2002-03-28 Merck Patent Gesellschaft Mit Beschraenkter Haftung 4-amino-quinazolines
WO2003097615A1 (en) 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
US7189733B2 (en) * 2003-03-12 2007-03-13 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
TWI289217B (en) * 2004-07-16 2007-11-01 Hon Hai Prec Ind Co Ltd Light guide plate
US7928107B2 (en) * 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US7718658B2 (en) * 2004-09-02 2010-05-18 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
US8283354B2 (en) * 2004-09-02 2012-10-09 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
WO2006066044A2 (en) * 2004-12-17 2006-06-22 Vertex Pharmaceuticals Incorporated Processes for producing 4-aminoquinazolines
ATE540033T1 (de) 2005-11-14 2012-01-15 Vertex Pharma Als modulatoren von spannungsgesteuerten ionenkanälen geeignete chinazoline

Also Published As

Publication number Publication date
UY28215A1 (es) 2004-09-30
CL2004000409A1 (es) 2005-01-07
JP2006522119A (ja) 2006-09-28
CA2517844A1 (en) 2004-09-16
JP5247027B2 (ja) 2013-07-24
US7678802B2 (en) 2010-03-16
IL170636A (en) 2012-08-30
ES2338553T3 (es) 2010-05-10
NO20054546D0 (no) 2005-10-03
HK1088314A1 (en) 2006-11-03
TW200426147A (en) 2004-12-01
RU2378260C2 (ru) 2010-01-10
AR044502A1 (es) 2005-09-14
US8343980B2 (en) 2013-01-01
US20040248890A1 (en) 2004-12-09
NZ542664A (en) 2009-03-31
US20110021495A1 (en) 2011-01-27
NO20054546L (no) 2005-11-25
AU2004217891B2 (en) 2011-06-23
DE602004024873D1 (de) 2010-02-11
KR20050108379A (ko) 2005-11-16
RU2005130486A (ru) 2006-05-10
EP1608632A1 (de) 2005-12-28
WO2004078733A1 (en) 2004-09-16
BRPI0408026A (pt) 2006-02-07
EP1608632B1 (de) 2009-12-30
AU2004217891A1 (en) 2004-09-16
PE20041059A1 (es) 2005-02-07

Similar Documents

Publication Publication Date Title
DE602004024873D1 (de) Chinazolin-verbindungen als ionenkanal modulatoren
ECSP066436A (es) Compuestos heterociclicos fusionados
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
SE0301569D0 (sv) Novel compounds
DK2217031T3 (da) Effektiv signalisering via adgangskanal
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
DK1667992T3 (da) Quinazolinderivater
DK1581535T3 (da) Pyrrolopyridazinderivater
ATE456558T1 (de) Gabanerge modulatoren
EP1723123A4 (de) Ionenkanalmodulatoren
EP1723117A4 (de) Ionenkanal-modulatoren
DE602004017782D1 (de) Substituierte arylpyrazole als parasitizide
EP1722783A4 (de) Ionenkanal-modulatoren
IS8228A (is) Ný asetídínefnasambönd
FR2850028B1 (fr) Passe-guide
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
IS8089A (is) Efnasambönd
EP1722788A4 (de) Ionenkanalmodulatoren
ATE540033T1 (de) Als modulatoren von spannungsgesteuerten ionenkanälen geeignete chinazoline
DK1581307T3 (da) Irs modulatorer
EP1723120A4 (de) Ionenkanal-modulatoren
EP1662512A4 (de) Mischionenleiter
NO20031736D0 (no) Forbindelser
DE502004012042D1 (de) Lichtleitanordnung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608632

Country of ref document: EP